高危型人乳头状瘤病毒16，18型DNA检测在宫颈病变筛查中的应用价值

检验医学 ›› 2012, Vol. 27 ›› Issue (5): 393-395.

高危型人乳头状瘤病毒16，18型DNA检测在宫颈病变筛查中的应用价值

周斌¹,左新华²,傅新文³

1.鹰潭市人民医院，江西鹰潭 335000；2.鹰潭市中医院，江西鹰潭 335000; 3.江西省人民医院，江西南昌 330006

收稿日期:2012-03-16 修回日期:2012-03-08 出版日期:2012-05-30 发布日期:2012-05-10
通讯作者: 傅新文，联系电话：0791-88695087。
作者简介:周　斌，男，1973年生，学士，副主任医师，主要从事检验医学工作。

The detective value of high-risk human papillomavirus genotype 16 and 18 DNA in screening cervical lesions

1. Yingtan People′s Hospital， Jiangxi Yingtan 335000，China; 2. Yingtan Hospital of Traditional Chinese Medicine, Jiangxi Yingtan 335000, China; 3. Jiangxi Provincial People′s Hospital, Jiangxi Nanchang 330006, China

Received:2012-03-16 Revised:2012-03-08 Online:2012-05-30 Published:2012-05-10

摘要/Abstract

摘要： 目的　评价高危型人乳头状瘤病毒16，18型(HPV16,18) DNA检测在宫颈病变筛查中的价值。方法　收集209例病理组织学结果为癌及癌前病变［宫颈上皮内瘤变(CIN)Ⅰ、CINⅡ、CINⅢ、宫颈浸润癌］和296例病理组织学为良性病变（炎症、息肉等），并同时做了液基细胞学检查、HPV16,18 DNA检测的病例，统计比较HPV16,18 DNA检测与液基细胞学检查对癌及癌前病变的敏感性、特异性及阴性预测值;比较不同病变程度分类患者中HPV16,18的检出率。结果　209例癌及癌前病变患者中HPV16,18阳性158例，液基细胞学阳性［低级别鳞状上皮内病变（LSIL)、不除外高级别鳞状上皮细胞(ASC-H)、高级别鳞状上皮内病变(HSIL)、鳞状细胞癌］128例。296例宫颈良性病变患者HPV16,18阳性43例，液基细胞学阳性2例。HPV16,18 DNA检测对癌及癌前病变的敏感性为75.6%，液基细胞学为61.2%，两者比较差异有统计学意义(χ²＝12.69，P<0. 01)，HPV16,18 DNA对癌及癌前病变的检出率明显高于液基细胞学。HPV16,18 DNA检测特异性为85.5%，阴性预测值为83.2%;液基细胞学特异性为99.3%，阴性预测值为78.4%;CINⅡ病变的HPV阳性检出率明显高于CINⅠ(χ²＝6.69，P<0.05)。结论　高危型HPV16,18感染与宫颈癌及宫颈癌前病变的发生、发展密切相关，HPV16,18 DNA检测对癌前病变和宫颈癌的敏感性高于液基细胞学、特异性低于液基细胞学，对宫颈炎、息肉等良性病变的阴性预测值高于液基细胞学，检测HPV16,18 DNA有着重要的临床价值。

关键词: 人乳头状瘤病毒, 高危16;18型, 液基细胞学, 宫颈癌, 宫颈上皮内瘤变

Abstract: Objective　To evaluate the detective value of high-risk human papillomavirus (HPV) genotype 16 and 18 (HPV16,18) in screening cervical lesions. Methods　By histological biopsy, 209 cases were cancer and percancerous lesions ［cervical intraepithelial neoplasia (CIN) Ⅰ, CIN Ⅱ, CIN Ⅲ and invasive cervical cancer］, and 296 cases were inflammation, polyp and other benign lesions. HPV16，18 DNA and liquid-based cytology were used to detect the cases with cancer and percancerous lesions by histological biopsy. Comparing the results of the 2 methods， HPV16，18 infectious rates， sensitivity， specificity and negative predictive value were statistically analyzed. Results　Of 209 patients with cancer and precancerous lesions，158 cases were positive of HPV16，18，and 128 cases were positive of liquid-based cytology ［low-grade squamous intraepithelial lesion (LSIL), atypical squamous cells, cannot exclude a high-grade squamous intraepithelial lesion (ASC-H), high-grade squamous intraepithelial lesion (HSIL) and squamous cell carcinoma］. Among the 296 patients with benign lesions, 43 cases were positive of HPV16,18, and 2 cases were positive of liquid-based cytology. The results of cancer and precancerous lesions showed that the positive rate of HPV16，18 DNA was higher than that of liquid-based cytology (χ²＝12.69，P<0.01). The sensitivity， specificity and negative predictive value of HPV16，18 DNA were 75.6%， 85.5% and 83.2% respectively, and 61.2%, 99.3% and 78.4% of liquid-based cytology. The HPV16,18 positive rate of CIN Ⅱ was obviously higher than that of CINⅠ(χ²＝6.69，P<0.05). Conclusions　The occurrence of cervical cancer and percancerous lesions is closely related to HPV16,18 infection. Compared with liquid-based cytology，HPV16，18 DNA in cervical cancer and percancerous lesions has a higher sensitivity，lower specificity and higher negative predictive value. HPV16，18 DNA has an important clinical value for screening cervical benign lesions, and it is better than liquid-based cytology.

Key words: Human papillomavirus, High-risk human papillomavirus genotype 16 and 18, Liquid-based cytology, Cervical cancer, Cervical intraepithelial neoplasia

周　斌;左新华;傅新文. 高危型人乳头状瘤病毒16，18型DNA检测在宫颈病变筛查中的应用价值[J]. 检验医学, 2012, 27(5): 393-395.

ZHOU Bin;ZUO Xinhua;FU Xinwen. The detective value of high-risk human papillomavirus genotype 16 and 18 DNA in screening cervical lesions[J]. , 2012, 27(5): 393-395.

[1]	张亚旭, 崔延伟, 刘紫烟. 核酸分子杂交-流式细胞术检测HPV E6/E7 mRNA初步研究[J]. 检验医学, 2023, 38(1): 46-50.
[2]	张晓英. 宫颈癌患者新辅助化疗前后TK1、ID-1水平变化与疗效的关系[J]. 检验医学, 2020, 35(2): 108-111.
[3]	谌琼华. HPV DNA分型检测在宫颈病变及宫颈癌鉴别诊断中的价值[J]. 检验医学, 2019, 34(6): 498-501.
[4]	黄燕, 朱晓云, 李天英. 人乳头瘤病毒DNA检测联合液基细胞学检查在宫颈病变筛查中的意义[J]. 检验医学, 2019, 34(4): 313-317.
[5]	蔡鹏飞, 许泽辉, 王敬仁, 严提珍. 广西柳州地区9 810例人乳头瘤病毒检测结果分析[J]. 检验医学, 2019, 34(3): 246-248.
[6]	杨阳, 陈良远, 曹鹏驹, 陈少婷, 张秋琴, 黄春莉, 吴秋妹, 陈发林. 福州地区体检女性HPV感染及基因亚型分析[J]. 检验医学, 2019, 34(2): 144-147.
[7]	孙永梅, 陈兆武, 张扬, 万玲玲, 李明, 邓芳. 安徽地区宫颈癌患者HPV感染状况及其在放疗疗效监测中的应用[J]. 检验医学, 2019, 34(10): 897-900.
[8]	轩乾坤, 郭建, 吴文娟, 李广波. 人乳头瘤病毒E6/E7 mRNA检测的临床应用[J]. 检验医学, 2018, 33(7): 640-643.
[9]	黄群欢, 洪岭, 陶春林, 黄旭红. 不同分期宫颈癌患者外周血Treg和相关细胞因子差异分析[J]. 检验医学, 2017, 32(9): 769-772.
[10]	颜晓慧, 林金端. 人乳头瘤病毒感染与宫颈病变程度的关系[J]. 检验医学, 2017, 32(8): 700-703.
[11]	赵培玉, 陈敖峥, 秦锦龙, 宋力雯, 成佳景. Cervista HR-HPV DNA检测联合TCT在宫颈癌筛查中的临床价值[J]. 检验医学, 2017, 32(4): 322-325.
[12]	张雪丹, 翁跃颂. HPV DNA分型联合“三阶梯”技术对子宫颈癌前病变诊断及预后判断的价值[J]. 检验医学, 2017, 32(11): 990-993.
[13]	徐萍, 方筠, 应春妹. 高危型HPV DNA检测与细胞学检查用于宫颈疾病诊疗筛查的结果分析[J]. 检验医学, 2016, 31(6): 516-520.
[14]	刁雯静, 孙红, 郭奇桑, 王丽, 陶祥, 隋龙. cornulin在宫颈病变中的表达及其差异[J]. 检验医学, 2015, 30(9): 898-902.
[15]	尧荣凤，赵旭鸿，李智，薛龙，许国祥. 不同年龄段女性人乳头瘤病毒感染状况分析[J]. 检验医学, 2014, 29(7): 708-711.